Literature DB >> 531481

Serum bile acids after a test meal in Crohn's disease.

K Samuelson, C Johansson, A Norman.   

Abstract

The serum levels of conjugated cholic and chenodeoxycholic acid have been studied before and during a 4 h period after the intake of a liquid test meal in seven control subjects and in fourteen patients with Crohn's disease. The concentrations of serum bile acids were determined by radioimmunoassay. The control group showed a postprandial increase of both conjugates with a return to the fasting level for cholic acid within 4 h. The chenodeoxycholic acid conjugate did not return to the fasting level within the test period. The serum bile acid concentration in Crohn's disease divided the patients in two groups; one group with decreased or normal fasting levels and low postprandial increase and another group with elevated fasting levels and a postprandial increase without return to the fasting levels within the test period.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 531481     DOI: 10.1080/00365517909108828

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  3 in total

1.  Liver function tests and urinary albumin in house painters with previous heavy exposure to organic solvents.

Authors:  I Lundberg; G Nise; G Hedenborg; M Högberg; O Vesterberg
Journal:  Occup Environ Med       Date:  1994-05       Impact factor: 4.402

2.  Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease.

Authors:  Carsten Gnewuch; Gerhard Liebisch; Thomas Langmann; Benjamin Dieplinger; Thomas Mueller; Meinhard Haltmayer; Hans Dieplinger; Alexandra Zahn; Wolfgang Stremmel; Gerhard Rogler; Gerd Schmitz
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

3.  Ileal dysfunction in Crohn's disease assessed by the postprandial serum bile acid response.

Authors:  F S Suchy; W F Balistreri
Journal:  Gut       Date:  1981-11       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.